Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 September 2023 - 10:00PM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-classi therapeutics that
combine both targeted and immune-mediated mechanisms, announced
today that Sam Whiting, M.D., Ph.D., chief medical officer of
Tempest, will present at the H.C. Wainwright 25th Annual Global
Investment Conference.
The company presentation will be available for
on-demand viewing Monday, September 11, 2023, at 7:00 a.m. ET on
the investor section of the Tempest website at
https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company has a diverse portfolio
of novel programs ranging from early research to investigation in a
randomized global study in first-line cancer patients. The
company’s two clinical programs, TPST-1120 and TPST-1495, target
PPARα and EP2/EP4, respectively, and are advancing through trials
designed to study the agents as monotherapies and in combination
with approved agents. TPST-1120 is currently being evaluated in
first line hepatocellular carcinoma (HCC) in combination with
atezolizumab and bevacizumab, the standard of care for first-line
HCC, in a Phase 1b/2 randomized global study where an early data
cut demonstrated positive results in multiple categories; the
company expects the formal data set in the second half of 2023.
TPST-1495 is being evaluated in combination with pembrolizumab in a
Phase 1b expansion cohort in patients with advanced endometrial
cancer. Tempest is also developing an orally available inhibitor of
TREX1, a target that controls activation of the cGAS/STING pathway.
Tempest is headquartered in Brisbane, California. More information
about Tempest can be found on the company’s website at
www.tempesttx.com.
Investor Contacts:
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
________________________i If approved by the FDA
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Sep 2023 to Sep 2024